Sofosbuvir/velpatasvir/voxilaprevir

Sofosbuvir/velpatasvir/voxilaprevir is a fixed-dose combination medication used in the treatment of hepatitis C. It contains three active ingredients: sofosbuvir, velpatasvir, and voxilaprevir. This combination therapy is marketed under the brand name Vosevi by Gilead Sciences.

Composition

The medication is composed of three direct-acting antiviral drugs: sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir is a nucleotide analogue hepatitis C virus (HCV) NS5B polymerase inhibitor, velpatasvir is an HCV NS5A inhibitor, and voxilaprevir is an HCV NS3/4A protease inhibitor.

Usage

Sofosbuvir/velpatasvir/voxilaprevir is used to treat adults with chronic hepatitis C genotype 1-6, either without cirrhosis or with compensated cirrhosis, who have previously been treated with an NS5A inhibitor-containing regimen.

Efficacy

Clinical trials have shown that the combination of sofosbuvir, velpatasvir, and voxilaprevir is highly effective in curing hepatitis C. The cure rates are typically over 90%, even in patients with cirrhosis or those who have previously failed other treatments.

Side Effects

Common side effects of sofosbuvir/velpatasvir/voxilaprevir include headache, fatigue, diarrhea, and nausea. Serious side effects may include reactivation of hepatitis B in those who have previously been infected.

Approval

The combination of sofosbuvir, velpatasvir, and voxilaprevir was approved for medical use in the United States in 2017. It is on the World Health Organization's List of Essential Medicines.

See Also

• Hepatitis C treatment
• Direct-acting antivirals
• Gilead Sciences